Skip to NavigationSkip to content

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Cerebral Palsy in 8 Major Markets - ref #BS000022

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Cerebral Palsy in 8 Major Markets

Cerebral Palsy lacks a precise definition as it is not a single disease, but an umbrella term describing non-progressive brain lesions involving motor or postural abnormalities that are noted in early development. The exact pathological mechanisms and processes that cause Cerebral Palsy are largely unknown. However, premature birth, exposure to infection or radiation during pregnancy and post-natal head injuries are all associated risk factors in developing Cerebral Palsy.

This report provides the current prevalent population for Cerebral Palsy across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Cerebral Palsy have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Cerebral Palsy include:

  • Low weight at birth
  • Premature birth (pre-term)
  • Epilepsy and seizures
  • Sensory impairment
  • Congenital malformations

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reasons to buy

  • Able to quantify patient populations in global Cerebral Palsy’s market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Cerebral Palsy and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Cerebral Palsy’s prevalent population.
  • Identify sub-populations within Cerebral Palsy which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Cerebral Palsy patients.

Publisher: Black Swan
Publication date: November 2015 

Price: £ 3,950.00

You need to agree to the Terms and Conditions before placing your order

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches